Hosni assumed his current role in 2021. He led the Jamjoom Pharma listing on the Saudi Exchange (Tadawul) in June 2023. The company has manufacturing facilities in Saudi Arabia and Egypt as well as sales operations in key markets such as the U.A.E., Bahrain, Kuwait, Oman, Iraq, Egypt, Morocco and Algeria with a workforce of 1,300 people. The company recorded revenues of $102.8 million and net profits of $27.4 million in Q1 2024. The company had a market cap of $2.7 billion, as of July 18, 2024. Hosni was previously the regional president for Africa and the Middle East at Pfizer, and commercial director for Egypt and Sudan at GSK.